NeuroOne Medical Technologies Corporation (NMTC) Stock Forecast
NMTC analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 3 analysts
- Price target
- $7.27 average of analyst targets
- Upside to target
- +656.2% from the latest close
- Next earnings
- —
- 52-week range
- $0.96 – $5.88
NMTC analyst ratings
3 analystsNumber of analysts at each rating.
NMTC price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NMTC earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next quarter (Dec '26) | −$0.17 | −$0.22 | −$0.14 | −$0.18 | +5.6% | 3 |
| Current fiscal year (FY2026) | −$0.71 | −$0.88 | −$0.39 | −$0.54 | −32.1% | 3 |
| Next fiscal year (FY2027) | −$0.63 | −$0.78 | −$0.41 | −$0.71 | +11.2% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NMTC revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next quarter (Dec '26) | $3.3M | $3.1M | $3.9M | +15.6% | 3 |
| Current fiscal year (FY2026) | $10.5M | $10.5M | $10.5M | +15.7% | 1 |
| Next fiscal year (FY2027) | $13.3M | $11.0M | $14.5M | +26.6% | 3 |
NMTC EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NMTC revenue: reported and forecast
NMTC EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next quarter (Dec '26) | −$0.15 | −$0.15 | −$0.17 | −$0.17 | −$0.17 | +15.9% | 0 up · 2 down |
| Current fiscal year (FY2026) | −$0.84 | −$0.84 | −$0.74 | −$0.74 | −$0.71 | −15.1% | 1 up · 0 down |
| Next fiscal year (FY2027) | −$0.51 | −$0.51 | −$0.63 | −$0.63 | −$0.63 | +23.4% | 0 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NMTC earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NMTC beat in 7 of 12.
What analysts expect from NMTC
3 analysts cover NeuroOne Medical Technologies; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.27, 656.2% above the latest close of $0.96. Analysts expect earnings of −$0.71 per share for FY2026, −32.1% from a year earlier. For FY2027 the average estimate is −$0.63 per share on revenue of $13.3 million. NeuroOne Medical Technologies beat the EPS estimate in 7 of the last 12 quarters.
Related: NMTC income statement, NMTC key metrics, NMTC chart. See the NMTC stock overview for the latest quote and news.
NMTC forecast FAQ
What is NeuroOne Medical Technologies's price target?
The average analyst price target for NeuroOne Medical Technologies is $7.27, 656.2% above the latest close of $0.96.
Is NeuroOne Medical Technologies a buy, hold or sell?
Of 3 analysts covering NeuroOne Medical Technologies, 2 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is NeuroOne Medical Technologies's EPS forecast?
Analysts forecast −$0.71 per share for FY2026 (range −$0.88 to −$0.39); for FY2027 the estimate is −$0.63.
What is NeuroOne Medical Technologies's revenue forecast?
The average revenue estimate for FY2026 is $10.5 million, growth of 15.7%; for FY2027 it is $13.3 million.
Does NeuroOne Medical Technologies usually beat earnings estimates?
NeuroOne Medical Technologies reported EPS at or above the analyst estimate in 7 of the last 12 quarters.